Pelvic pain is the main clinical manifestation associated with endometriosis, a disorder caused by endometrial tissues growing outside the uterus. Pain relievers, hormonal contraceptives, aromatase inhibitors, androgenic agents, and gonadotropin-releasing hormone (Gn-RH) agonists are currently used to manage endometriosis-associated pelvic pain. However, more-efficacious and more easily administered medical options remain a high unmet need. The launches of second-generation, orally administered Gn-RH antagonists will significantly expand the endometriosis therapeutic market by 2026.

Questions Answered:

  • Endometriosis usually affects women of reproductive age. How large are the diagnosed prevalent endometriosis populations in the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom)? What percentage of diagnosed endometriosis patients received drug treatment in 2016? How will the drug-treated rate change in 2026?
  • We expect that by 2024, three Gn-RH antagonists will be launched. What clinical role will second-generation, oral Gn-RH antagonist therapies play in the management of endometriosis? What are clinical advantages of Gn-RH antagonists compared with Gn-RH agonists?
  • AbbVie’s elagolix is the most advanced oral Gn-RH antagonist in development. How will elagolix be differentiated from other emerging Gn-RH antagonists—relugolix and OBE-2109 in the endometriosis therapeutic market?Which emerging Gn-RH antagonists will enjoy the greatest clinical and commercial success by 2026?


Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Six country-specific interviews with endometriosis specialists.

Epidemiology: Diagnosed and drug-treated prevalent cases.

Emerging therapies: Phase III/PR: 2; Phase II: 3; coverage of select preclinical and Phase I products.

Market forecast: Drug-level sales and patient share of key endometriosis therapies in 2026.  

Key companies:  AbbVie, Bayer, Myovant, ObsEva, Repros.

Key drugs: elagolix, relugolix, OBE-2109, leuprolide, telapristone, vilaprisan.

Table of contents

  • Endometriosis - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Jing Wu

Jing is a Principal business insights analyst in the infectious, niche, and rare diseases team at Decision Resources Group, focusing on a diverse set of key niche and rare diseases.

Jing completed her M.B.A. at Boston University with concentrations in health sector management and finance. She also holds an M.S. in biomedical science from the University of Massachusetts Medical School and a B.S. in biochemistry from Nanjing University in China. She worked as a research assistant at the Molecular Cardiology Research Institute of Tufts Medical Center, where she was involved in several projects to identify genetic regulators contributing to heart diseases.

Related Reports

Endometriosis - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of endometriosis comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets. We report both the diagnosed inci...

View Details

Endometriosis - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of endometriosis comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diag...

View Details